Dear Madam or Sir, Dear Shareholder,
On behalf of the entire Sensorion team, I am delighted to welcome you to our website’s Investors pages, which are specifically devoted to you. Since our Initial Public Offering on the Alternext market in Paris in April 2015, the success of which was in large part due to you, we have made solid breakthroughs on both the clinical and financial fronts.
With a strengthened financial structure and a diversified shareholder base, Sensorion is today well-positioned to make the most of its technological platform’s potential and accelerate the development of its drug candidate programs aimed at the symptomatic treatment of bouts of vertigo (SENS-111), at preventing and treating complications associated with progressive lesions in the inner ear (SENS-218) and at protecting the inner ear from the toxicity of chemotherapy (SENS-300).
Our R&D teams are intensifying their efforts to optimize clinical development timelines, notably by considering orphan or pediatric indications, that will allow a rapid progression on the necessary time scale for developing new drugs towards commercialization with the best use of our financial resources.
I would like to thank you for your trust and your support for Sensorion, whose ambition is to become a major player in the treatment of inner ear disorders.
Laurent Nguyen, CEO